Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.67 |
| ▸ | CA1 | P00915 | 1/20 | 0.67 |
| ▸ | CA2 | P00918 | 1/20 | 0.67 |
| ▸ | CA7 | P43166 | 1/20 | 0.67 |
| ▸ | CA9 | Q16790 | 1/20 | 0.67 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.67 |
| ▸ | PPARA | Q07869 | 2/20 | 0.61 |
| ▸ | FABP4 | P15090 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2698266 | 0.86 | CA12 (0.71) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5837680 | 0.85 | HDAC1 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8477214 | 0.84 | CA12 (0.69) | CA12CA1CA2CA7CA9 | |
| Hydrochloric Acid SCHEMBL17746095 | 0.84 | CA12 (0.69) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8477211 | 0.84 | CA12 (0.69) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7097468 | 0.83 | PPARA (0.63) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9394945 | 0.83 | CA12 (0.67) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7337783 | 0.83 | CA12 (0.67) | CA12CA1CA2CA7CA9 | |
| SCHEMBL22408017 | 0.81 | PPARA (0.78) | CA12CA1CA2CA7CA9 | |
| 2,6-Dimethoxybenzoic Acid SCHEMBL149926 | 0.81 | CA12 (1.00) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3303415-B1 | VISIBLE-LIGHT PHOTOINITIATORS AND USES THEREOF | ALCON INC (CH) | 2022-12-28 | — | — | EP | disclosed |
| US-10324311-B2 | Visible-light photoinitiators and uses thereof | NOVARTIS AG (CH) | 2019-06-18 | — | — | US | disclosed |
| EP-3303415-A1 | VISIBLE-LIGHT PHOTOINITIATORS AND USES THEREOF | Novartis AG (CH) | 2018-04-11 | — | — | EP | disclosed |
| US-20160357031-A1 | VISIBLE-LIGHT PHOTOINITIATORS AND USES THEREOF | ALCON INC. (CH) | 2016-12-08 | — | — | US | disclosed |
| WO-2016193912-A1 | VISIBLE-LIGHT PHOTOINITIATORS AND USES THEREOF | NOVARTIS AG (CH) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10324311-B2 | Visible-light photoinitiators and uses thereof | SIRT5, IK, IGLV6-57 | CA12 2901/4885CA1 2225/4885CA2 2281/4885 |
| US-20160357031-A1 | VISIBLE-LIGHT PHOTOINITIATORS AND USES THEREOF | SIRT5, IK, IGLV6-57 | CA12 2901/4885CA1 2225/4885CA2 2281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.